Restrizymes Biotherapeutics (U) LTD Africa's leading biotech company for new diagnostics, drugs and vaccines

We are a start up biotech focused on meeting the need for new diagnostics, therapeutics and or vaccines against infectious , rare genetic and immune diseasess that preferentially affect the people(s) of sub-Saharan Africa. We use genomics and related technologies to unveil molecular targets for the development of the next generation of interventions. Our most successful advanced prototypes include (i) a rapid diagnostic test (RDT) for ebola virus disease-EVD, (ii) HIV-1 gene therapy, (iii) TB LFT and Microfluidics rapid culture systems. With over 10 new molecular entities-NMEs in the offing, we aim to build a company net-worth of US$6-12 billion (premised on the market price of each NME of between US$600-to $1.2 billion)

Secteurs Biotechnologie et recherche médicale, Produits pharmaceutiques
Emplacement Ouganda
Etape Se connecter pour afficher les détails
Marchés Se connecter pour afficher les détails
Contact Se connecter pour afficher les détails
Les médias sociaux